Bristol-Myers Squibb Pravachol
Executive Summary
Supplemental NDAs for the use of pravastatin in the treatment of patients with Frederickson Type IV (S-026) and in the treatment of patients with Frederickson Type III (S-027) approved Jan. 18. The product also received approval for an optional starting dose of 40 mg/day (S-029) and for a change in time of dosing from administration at bedtime (S-030) to administration at any time of day with or without food